Baumann et al., évolution à long terme des infections par l’hépatite C, de leurs traitements et de leurs complications dans l’Etude suisse de cohorte VIH
L’épidémie en voie de disparition – évolution à long terme des infections par l’hépatite C, de leurs traitements et de leurs complications dans l’Etude suisse de cohorte VIH Les infections par le virus de l’hépatite C entraînent des maladies hépatiques et des décès dans le monde entier. Les personnes vivant avec une infection par le […]
Baumann et al., Langfristige Entwicklung von Hepatitis C Infektionen sowie deren Behandlungen und Komplikationen in der Schweizerischen HIV-Kohortenstudie
Die verschwindende Epidemie – langfristige Entwicklung von Hepatitis C Infektionen sowie deren Behandlungen und Komplikationen in der Schweizerischen HIV-Kohortenstudie Infektionen mit dem Hepatitis C-Virus führen weltweit zu Leberkrankungen und Todesfällen. Personen, die mit einer HIV-Infektion leben, sind durch Hepatitis C besonders gefährdet und sind deutlich häufiger betroffen. Das Hepatitis C Virus wurde erst 1987 identifiziert […]
Hilfiker et al., Mycobacterium tuberculosis infection and acute or subclinical CAD
Brief report: Mycobacterium tuberculosis infection and acute or subclinical coronary artery disease: the Swiss HIV Cohort Study This brief report from the Swiss HIV Cohort Study investigates whether Mycobacterium tuberculosis (MTB) infection is associated with acute coronary artery disease (CAD), or subclinical atherosclerosis in people living with HIV (PLWH) in a low tuberculosis (TB) prevalence […]
Kusejko et al., Inflammation and B cell activation define a plasma proteome signature predicting tuberculosis in people with HIV
A step forward in TB prediction for people living with HIV: Findings from the first large-scale proteome study in the SHCS Tuberculosis (TB) continues to be one of the most serious health threats for people living with HIV. While TB is caused by a bacterial infection and can often be treated, it can become life-threatening […]
Loosli et al., HIV-1-Medikamentenresistenz bei Menschen, die eine antiretrovirale Therapie auf Dolutegravir-Basis erhalten
HIV-1-Medikamentenresistenz bei Menschen, die eine antiretrovirale Therapie auf Dolutegravir-Basis erhalten: eine kollaborative Kohortenanalyse In den letzten Jahren ist das HIV-Medikament Dolutegravir (DTG) zu einem zentralen Bestandteil der HIV-Therapie weltweit geworden. Die Überwachung und Kontrolle von Resistenzen gegen Dolutegravir ist daher entscheidend für die nachhaltige Behandlung von fast 40 Millionen Menschen, die mit einer HIV Infektion […]
Kleynhans et al., Types of myocardial infarction in PWH in Switzerland
Types of myocardial infarction in people with HIV in Switzerland Cardiovascular disease is an important comorbidity in people with HIV. Myocardial infarction (MI) can occur as Type 1 due to atherosclerotic plaque rupture, or Type 2 due to an imbalance in oxygen supply and demand. In the US, up to 50% of MI in people […]
Groen et al., Footprints and decoys for IFN-I autoAbs
Type I interferon autoantibody footprints reveal neutralizing mechanisms and allow inhibitory decoy design In a recent study led by Kevin Groen and senior author Benjamin G. Hale, researchers uncovered how certain harmful autoantibodies can disrupt the body’s natural antiviral defenses—and proposed an innovative strategy to neutralize them. Published in the Journal of Experimental Medicine, this […]
Ballif et al., Willingness to participate in clinical trials and expectations towards ART among heavily treatment-experienced PLWH
Willingness to participate in clinical trials and expectations towards antiretroviral therapy among heavily treatment-experienced people living with HIV: A feasibility survey As people with HIV live longer on antiretroviral therapy (ART), many face multiple comorbidities and the challenges of polypharmacy, including drug–drug interactions (DDIs) from booster-containing regimens. In a study published in HIV Medicine, Ballif […]
Ballif et al., B-free ART for PWH and multidrug resistance
Booster-free anti-retroviral therapy for persons living with HIV and multidrug resistance (B-Free): protocol for a multicentre, multistage, randomised, controlled, non-inferiority trial The B-Free clinical trial is an investigator-initiated randomized clinical trial funded by the Swiss National Science Foundation and nested in the Swiss HIV Cohort Study. In this article, the authors present the trial and […]
Bartl et al., Machine learning to predict tuberculosis
Machine learning-based prediction of active tuberculosis in people with human immunodeficiency virus using clinical data Tuberculosis (TB) is a serious health concern for people living with HIV, who are at higher risk of developing active TB after infection. Early identification of who is at risk remains a major challenge, as current screening tests—such as the […]